FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Ty	pe Response	s)		_					1					
1. Name and Address of Reporting Person * EVNIN LUKE			2. Issuer Name and Ticker or Trading Symbol RIGEL PHARMACEUTICALS INC [RIGL]					5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director X 10% Owner						
(Last) (First) (Middle) C/O MPM ASSET MANAGEMENT, 111 HUNTINGTON AVENUE, 31ST FLOOR			3. Date of Earliest Transaction (Month/Day/Year) 08/31/2004				Office	r (give title belo	ow)	Other (specify	below)			
(Street) BOSTON, MA 02199			4. If Amendment, Date Original Filed(Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) Form filed by One Reporting Person X_ Form filed by More than One Reporting Person						
(City		(State)	(Zip)	1	Γable I - No	n-D	erivative	Securi	ties Acqui	red, Disp	osed of, or I	Beneficially	Owned	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	f Code (Instr. 8)		on 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		d of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)		Following	6. Ownership Form: Direct (D)	7. Nature of Indirect Beneficial Ownership	
			(Month Buy Tear)	Code	V	Amount	(A) or (D)	Price	(msu. 3	o una 1)		or Indirect (I) (Instr. 4)		
Common	Stock		08/25/2004		S		826 (1)	D	\$ 19.77	1,772,099			I	See Footnote (2)
Common Stock		08/31/2004		S		60,527	D	\$ 20.5962	1,711,572		I	See Footnote		
Common Stock		09/01/2004		S		24,500 (<u>5</u>)	D	\$ 21.1314	1,687,072		I	See Footnote (6)		
Reminder:	Report on a s	separate line	for each class of secu			Per cor the	rsons wh ntained i e form dis	no res n this splays	form are s a curre	not requ ntly valid	ction of inf ired to res OMB cont	spond unle	ess	2 1474 (9-02)
T			1 able 11 -	Derivative Securi (e.g., puts, calls, v						ly Owned	1	T		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transacti Date (Month/Day	Execution D any	4. Transactior Code (Instr. 8)	5. Number of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	and (M	and Expiration Date (Month/Day/Year) A U So (I 4)		e Amo Und Secu	tle and ount of erlying crities r. 3 and	nt of Hying dities and Derivative Security (Instr. 5)		Owners Form o	f Beneficia Ownershi y: (Instr. 4)
				Code V	(A) (D)			Expira Date	ation Title	Amount or Number of Shares				

Reporting Owners

	Relationships				
Reporting Owner Name / Address	Director	10% Owner	Officer	Other	
EVNIN LUKE C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR BOSTON, MA 02199		X			

GADICKE ANSBERT		
C/O MPM ASSET MANAGEMENT 111 HUNTINGTON AVENUE, 31ST FLOOR	X	
BOSTON, MA 02199		

Signatures

/s/ Luke Evnin	09/02/2004		
**Signature of Reporting Person	Date		
/s/ Ansbert Gadicke	09/02/2004		
**Signature of Reporting Person	Date		

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) See Form 4 filed for MPM BioVentures III-QP, L.P. for additional members of this joint filing. The shares were sold as follows: 826 by Kurt Wheeler.

 The shares are held as follows: 99,181 by MPM BioVentures III, L.P. ("BVIII"); 4,162 by MPM BioVentures III-QP, L.P. ("BVIII QP"); 352 by MPM BioVentures III GmbH & Co. Beteiligungs KG ("BVIII KG"); 126 by MPM BioVentures III Parallel Fund, L.P. ("BVIII PF"); and 80 MPM Asset Management Investors 2003 BVIII LLC
- (2) ("BVAM LLC"). MPM BioVentures III GP, L.P. ("BVIII GP") and MPM BioVentures III LLC ("BVIII LLC") are the direct and indirect partners of BVIII, BVIII QP, BVIII PF and BVIII KG. Luke Evnin, Ansbert Gadicke, Nicholas Galakatos, Dennis Henner, Nicholas Simon, III, Michael Steinmetz and Kurt Wheeler are the members of BVIII LLC and BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (3) The shares were sold as follows: 3,388 by BVIII; 50,384 by BVIII QP; 4,258 by BVIII KG; 1,522 by BVIII PF; and 975 BVAM LLC.
- (4) The shares are held as follows: 95,793 by BVIII; 1,424,746 by BVIII QP; 120,409 by BVIII KG; 43,029 by BVIII PF; and 27,595 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- (5) The shares were sold as follows: 1,371 by BVIII; 20,394 by BVIII QP; 1,724 by BVIII KG; 616 by BVIII PF; and 395 BVAM LLC.
- (6) The shares are held as follows: 94,422 BVIII; 1,404,352 by BVIII QP; 118,685 by BVIII KG; 42,413 by BVIII PF; and 27,200 by BVAM LLC. Each member of the group disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.